Drug Trial Radar · NCT05604417
Zandelisib + Tazemetostat in R/R Follicular Lymphoma
Last checked: Nov 19, 2026Latest source record: Jul 7, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Jan 2023
Primary completion
Dec 1, 2024
Study completion Dec 1, 2026
Sponsor
- Lead sponsor
- Jacob Soumerai, MDAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- MEI Pharma, Inc.
- First posted
- Nov 3, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This research study is being done to estimate the safety and efficacy of zandelisib and tazemetostat in people with relapsed or refractory follicular lymphoma (FL) This research study involves Zandelisib in combination with Tazemetostat. MEI Pharma, Inc, a biotechnology company, is supporting this research study by providing funding for the research study, including the study drug zandelisib.
Conditions
- Relapsed Follicular Lymphoma
- Refractory Follicular Lymphoma
Interventions
TAZEMETOSTATDrug
Dosage and treatment timings per protocol
ZandelisibDrug
Dosage and treatment timings per protocol
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Limiting Toxicities Phase ITime frame: Up to 28 days
- Complete Response Rate Phase IITime frame: up to 4 years
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.